Velasof 400/100mg (Sofosbuvir/Velpatasvir)

Velasof 400/100 mg (Sofosbuvir/Velpatasvir) – A Comprehensive Overview

Brand Name: Velasof
Generic Name: Sofosbuvir 400 mg + Velpatasvir 100 mg
Manufacturer: Hetero Healthcare
Form: Film-coated Tablet
Route of Administration: Oral
Therapeutic Class: Antiviral (Direct-Acting Antiviral – DAA)
Prescription Required: Yes

Product Description

Velasof 400/100 mg is a fixed-dose combination antiviral medicine designed to cure the chronic Hepatitis C virus (HCV) infection. It is a potent combination of active components — Sofosbuvir (400 mg) and Velpatasvir (100 mg). They are part of the category of antivirals that act directly (DAAs) and work by blocking different proteins that the hepatitis C virus needs in order to reproduce and live.

Velasof has been designed to be an effective multi-genotypic therapy, which means it can be highly effective against all of the major variants (1 to 6) in the Hepatitis C virus, which makes it an excellent choice for those from diverse areas and forms. The treatment has changed the way HCV is treated, providing excellent cure rates and shorter durations of treatment as well as fewer side effects in comparison to earlier treatment options like interferon-based treatments.

Indications (Uses)

Velasof is recommended for the treatment of:

• Chronic Hepatitis C infection in adolescents and adults with a minimum age of 12 years or with a weight of more than 35kg
• Genotypes 1 through 6
• HCV patients with or without compensated cirrhosis (Child-Pugh A)
• Patients with HCV who have chronic cirrhosis (Child-Pugh C or B), when combined with the drug ribavirin
• HCV/HIV co-infection (as part of an appropriate antiretroviral regimen)
• Patients who have failed prior HCV treatments (including NS5A-inhibitor-experienced individuals)

Mechanism of Action

Velasof is a combination of two antiviral drugs that focus on different stages of the replication process of viral infections:

• Sofosbuvir is an analog of nucleotides of NS5B, a polymerase inhibitor. It’s converted by the body into a pharmacologically active triphosphate type that inhibits the HCV RNA-dependent RNA polymerase (NS5B), which is a crucial enzyme involved in HCV replication.
• Velpatasvir can be described as an NS5A inhibitor that blocks the HCV NS5A protein. It is vital for viral RNA replication and assembly.

Together, they make an effective combination that blocks the replication of viruses and triggers the development of a sustained virologic response (SVR), which is considered to be a treatment of the illness.

Dosage and Administration

• Recommended Dose: One tablet of Velasof (400 mg Sofosbuvir + 100 mg Velpatasvir) once daily, with or without food.
• Duration of Therapy:
  • For most patients (genotypes 1–6 without cirrhosis or with compensated cirrhosis): 12 weeks
  • For patients with decompensated cirrhosis: 12 weeks with ribavirin
• Pediatric Use: The product is approved for use by adolescents who are 12 years or over and weighing less than 35kg.
• Missed Dose: If you miss a dose, then take it as quickly as you can remember. When it’s getting close to another dose, don’t take the dose you missed — avoid double-dosing.

Important Note:

Velasof is not to be combined with other medications that contain Sofosbuvir. Always follow the guidelines for prescriptions by a certified healthcare professional.

Benefits of Velasof

• Pan-genotypic treatment: The drug is safe for all HCV genotypes.
• High cure rates: SVR12 rates of 95–99% in clinical trials
• Once-daily dosing: Enhances the patient’s adherence
• Short treatment course: Typically 12 weeks
• Well-tolerated: A lower incidence of serious adverse events when compared to earlier treatments
• No need for interferon: It is safe from the negative side effects of interferon-based treatments.
• Co-infection management: It is effective in co-infected HIV/HCV patients.
• Suitable for liver disease patients: Useful in conjunction with the ribavirin treatment in decompensated cirrhosis

Side Effects

As with all medicines, Velasof may cause side effects. However, not everybody suffers from them. Most of the side effects are not severe and temporary.

Common Side Effects (may affect more than 1 in 10 people):

• Headache
• Fatigue
• Nausea
• Insomnia

Less Common Side Effects:

• Irritability
• Diarrhea
• Muscle aches
• Dizziness
• Skin rash

When combined with ribavirin, additional side effects may include:

• Anemia
• Shortness of breath
• Cough
• Depression
• Loss of appetite

Get medical attention immediately if you notice symptoms that indicate an allergy, such as itching, rash, or breathing difficulties.

Warnings and Precautions

• Pregnancy and Breastfeeding: Do not recommend for lactation or during pregnancy unless recommended by a healthcare professional. Ribavirin, if used together, is contraindicated in pregnant women.
• Drug Interactions: Velasof may interact with medications like:
  • Rifampin and other rifamycins
  • Antacids (aluminum/magnesium)
  • Proton pump inhibitors
  • Certain anticonvulsants (e.g., phenytoin, carbamazepine)
  • Amiodarone (may cause bradycardia when combined with Sofosbuvir)
• Renal and Hepatic Impairment: A dose adjustment is not required in cases of mild to moderate impairment. Use caution when you are in extreme situations.
• HIV/HCV Co-infection: Check for HIV viral breakout; co-administration with antiretrovirals can need dosage changes.

Contraindications

• Hypersensitivity to Sofosbuvir, Velpatasvir, or any other component in the formulation
• Utilize potent stimulants of P-glycoprotein, or CYP triggers (e.g., rifampin, St. John’s Wort)

Storage Instructions

• Maintain the storage in a cool and dry area at a temperature of 30°C (86°F)
• Make sure that the items are out of Children’s reach
• Be sure to protect yourself from moisture and light
• Use only up to the expiry date on the packaging

Packaging Information

• Pack Size: Typically, the bottles are 28 tablets (one month’s supply)
• Tablet Appearance: Film-coated tablet, oval-shaped

Frequently Asked Questions (FAQs)

1. How quickly will Velasof start working?
   A majority of patients see a decrease in viral load during the first couple of weeks after treatment. But the entire treatment (usually 12 weeks) should be followed to achieve the best result.
2. Can Velasof cure hepatitis C permanently?
   Yes. The achievement of the SVR12 (sustained virologic response 12 weeks after treatment) is believed to be a cure for more than 90% of patients.
3. Can I drink alcohol while on Velasof?
   Alcohol may stress the liver and hamper the recovery process. Avoid drinking the consumption of alcohol while you are in treatment.
4. What happens if I stop treatment early?
   Refraining from treatment too early can increase the chance of developing resistance to treatment and failing. Make sure you complete the entire treatment as directed.
5. Is generic Velasof as effective as branded Epclusa?
   Yes. Velasof includes all of the active ingredients found in Epclusa (the brand name originally developed and produced by Gilead) and has been approved as a comparable generic for therapeutic purposes that offers the same safety and efficacy quality at a lower cost.

Conclusion

Velasof 400/100 mg is a revolutionary antiviral medicine that eases and speeds up the treatment of chronic Hepatitis C. It is a powerful drug thanks to its broad coverage, which is pan-genotypic and has a high rate of cure. Velasof offers a transformative possibility for those suffering from this life-threatening liver condition. This is an enormous advancement in accessibility, ease of use, and clinical effects.

It is essential, however, to ensure that Velasof is administered under the guidance of a licensed healthcare professional and monitored regularly to get the highest possible outcome. If you’re diagnosed as having chronic HCV, the drug Velasof can provide possibilities for a full cure and a healthier future.